HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 125, Issue 3, 2001, Pages 485-491

  Viallard, J F ^a   Bloch Michel, C ^a   Neau Cransac, M ^b   Taupin, J L ^b   Garrigue, S ^a   Miossec, V ^b   Mercie, P ^a   Pellegrin, J L ^a   Moreau, J F ^b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Anti dsDNA; Antibodies; HLA DR; Lymphocyte activation; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NORMAL VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD8; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; RECURRENCE;

EID: 0035718029     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01623.x     Document Type: Article

References (31)

1. Sensitivity to change of three systemic lupus erythematosus disease activity indices: International validation
2. SLE: A rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up
3. Immunologic factors and clinical activity in systemic lupus erythematosus
4. Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features
5. Neuropsychiatric manifestations of systemic lupus erythematosus
6. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus
7. Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis
8. + T cells in systemic lupus erythematosus: Alterations associated with prednisolone therapy
9. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation
10. The 1982 revised criteria for the classification of systemic lupus erythematosus
11. Derivation of the SLEDAI: A disease activity index for lupus patients
12. Crosscultural validation and reliability of three disease activity indices in systemic lupus erythematosus
13. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study
14. Systemic lupus erythematosus
15. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE)
16. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study
17. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?
18. Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity
19. Serum IL-6, TNFalpha, p55srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus
20. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity
21. Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus
22. Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares
23. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases
24. The human Ia system
25. Analysis of fine-needle aspiration biopsies by flow cytometry in kidney transplant patients
26. Kinetic analysis of Ia expression on T cells in patients with systemic lupus erythematosus
27. + T cell abnormality in patients with active systemic lupus erythematosus: HLA-DR antigen expressions
28. Age-related changes in human blood lymphocyte subpopulations
29. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus
30. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)
31. B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus